ClinicalTrials.gg
CompletedNCT03239353Updated Jun 27, 2018

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects

A Phase 1 interventional study of Entecavir in HBV, sponsored by Aucta Pharmaceuticals, Inc. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-27.

Sponsored by Aucta Pharmaceuticals, Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a phase 1, randomized, parallel-group, single-center study in healthy adult subjects. The study will be conducted in two parts sequentially:

Part 1 is an open-label, two-arm, active-controlled design to evaluate the PK and safety of single oral dose of ETV XR tablet (1.5 mg) in healthy subjects. Part 1 will consist of 16 healthy subjects.

Part 2 is a double-blind, three-arm, placebo-controlled design to evaluate the PK and safety of higher oral doses of ETV XR tablet (3 mg and 6 mg) in healthy subjects. Part 2 will consist of 24 healthy subjects.

02

Conditions studied

  • HBV
03

In context

Lead sponsor

Aucta Pharmaceuticals, Inc is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects will be considered for enrollment in the study if they meet all of the inclusion criteria and none of the exclusion criteria.

  1. Male or female aged between 18 and 55 years (inclusive). Body weight ≥ 50 kg for males, and ≥45 kg for females and (BMI) between 18 and 28 kg/m2 (inclusive), BMI(kg/m2) = body weight(kg)/{height(m)}2;
  2. Ability to fully understand the purpose, characteristic, method and the possible adverse effects of the trial, and voluntarily signed obtained before any trial-related procedures are performed;
  3. Ability to comply with the requirements of this trial protocol, including refrain from strenuous exercise/activity 3 days prior to Day -1 (admission) and for 3 days prior to the Day 8, Day 15 and the final follow-up visit on Day 22through the duration of the study
  4. Have a (CLCr) ≥ 80 mL/min;
  5. Male subjects and female subjects of child bearing potential must be willing to practice effective during the study and been willing and able to continue contraception for 90 days after their dose of the study treatment;
  6. Male subjects must refrain from sperm donation from Day -1 through completion of the study and continuing for at least 90 days from the date of last dose of study drug;
  7. Subjects must refrain from blood donation from Screening through completion of the study and continuing for at least 30 days from date of last dose of study drug;
  8. , ALT and ≤ 1.5xULN (isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%);
  9. Must, in the opinion of the Investigator, be in good health based upon medical history, physical examination (including vital signs), and screening laboratory evaluations (hematology, chemistry, and urinalysis must fall within the normal range of the central laboratory reference ranges unless the results have been determined by the Investigator to have no clinical significance).

Exclusion criteria

Exclusion criteria:

A subject meeting any of the following criteria will be excluded from the study:

  1. Current or a history of any medical illness or medical disorders the investigator considers should exclude including (but not limited to) neurological disease, cardiovascular disease, hepatic or renal disease, gastrointestinal tract disease (such as dysphagia, gastrointestinal ulcers), respiratory disease, metabolism, skeletal system diseases or other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs;
  2. Has a positive result from serology examination for virus (HBV), virus (HCV), or (HIV);
  3. There are drug-dependent or drug abuse history, or urine drug abuse screening positive;
  4. Subject smoked more than 5 cigarettes or other tobacco or nicotine-containing products within 1 month prior to dosing and is unwilling to abstain from smoking for 48 hours prior to check-in (Day -1)ing, for the duration of the confinement period and at each follow-up visit;
  5. Has used an alcohol consumption of more than 14 units of alcohol per week (1 unit of alcohol is equivalent to 360 mL of beer or 45 mL of spirits with 40 % of alcohol or 150 mL of wine) within 6 months prior to screening or taking products containing alcohol 48 hours prior to IMP administration;
  6. Participated in any drug or medical device clinical trial within 3 months prior to screening;
  7. Pregnant or breastfeeding women or pregnancy testing is positive;
  8. Have taken any prescription medications, over-the-counter medications, supplements or herbal products within 14 days, or 5 half-lives (whichever is longer), of study drug dosing, with the exception of paracetamol and hormonal medications, unless in the opinion of the Investigator and/or Medical Monitor that the substance would not have any material impact on participant safety or the quality of study data;
  9. Donated blood greater than 400 mL or significant blood loss equivalent to 400 mL or received blood transfusion within 3 months of screening; Or donated blood greater than 200 ml or significant blood loss equivalent to 200 mL within 1 months prior to screening;
  10. Has infectious diseases within four weeks at screening (in the opinion of the investigator would pose a risk for participation in this study), severe trauma, or a history of major surgery within 3 months;
  11. Cannot tolerate venepuncture or cannulation;
  12. Consumption of grapefruit, grapefruit juice, cranberries, or products containing Seville oranges (fruit juices, marmalade, jam, etc) within 7 days prior to study drug dosing; consumption of caffeine-containing products within 48 hours of study drug dosing;
  13. Have been vaccinated within 90 days of study dosing, with the exception of licensed intranasal or intramuscular influenza vaccine ≤ 14 days prior to dosing.
  14. Have severe multiple allergies and / or severe allergies (including latex / heparin allergy) history, or has or significant intolerance to prescription drugs or over-the-counter drugs or food;
  15. Subjects who, in the opinion of the Investigator, should not participate in the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    1.5 mg ETV XR tablet

    Drug: Entecavir

  • Active comparator
    3 mg ETV XR tablet

    Drug: Entecavir

  • Active comparator
    6 mg ETV XR tablet

    Drug: Entecavir

  • Placebo comparator
    Placebo-to-match 1.5 mg ETV XR tablet

    Drug: Entecavir

  • Other
    0.5 mg ETV IR tablet

    Drug: Entecavir

Interventions

  • Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses in healthy subjects.

    Peak Plasma Concentration(Cmax)

    Time frame: 22 days

  2. To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses

    Area under the plasma concentration versus time curve (AUC)

    Time frame: 22 days

  3. To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses

    peak time (Tmax)

    Time frame: 22 days

  4. To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses

    Relative bioavailability (Frelative)

    Time frame: 22 days

  5. To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses

    half life (t1/2)

    Time frame: 22 days

Secondary outcomes

  1. To assess ETV XR tablet in healthy subjects.

    adverse events

    Time frame: 22 days

  2. To assess ETV XR tablet in healthy subjects.

    laboratory abnormalities

    Time frame: 22 day

  3. To assess ETV XR tablet in healthy subjects.

    vital signs

    Time frame: 22 days

  4. To assess ETV XR tablet in healthy subjects.

    12-lead electrocardiograms (ECGs)

    Time frame: 22 days

  5. To evaluate the dose linearity of ETV XR tablet

    1.5mg, 3mg and 6mg PK linearity

    Time frame: 60 days

07

Study locations

1 site
  • Linear Clinical Research Ltd
    Nedlands, Western Australia 6009, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in May 2018, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2017
First posted
Aug 4, 2017
StartActual
Oct 20, 2017
Primary completionActual
May 29, 2018
CompletionActual
Jun 20, 2018
Last update
Jun 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03239353
Lead sponsor
Aucta Pharmaceuticals, Inc
Responsible party
Sponsor
First posted
Aug 4, 2017
Start date
Oct 20, 2017
Primary completion
May 29, 2018
Completion
Jun 20, 2018
Last update
Jun 27, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entecavir

Start the discussion